2.1 Patients and data collection
This single-center prospective study was conducted between June 2019 and September 2020 at the First Affiliated Hospital of Guangxi Medical University, Guangxi, China. We enrolled patients aged <18 years with malignant hematological diseases who received voriconazole intravenously or orally for the prevention or treatment of IFI. The initial dose of voriconazole was administered in accordance with the drug label or the clinician’s experience, and adjusted according to the patient’s clinical response. The exclusion criteria were: (1) voriconazole failed to reach the steady-state described in the guidelines20or was replaced with other antifungal agents during the treatment; (2) undergoing hemodialysis or hemofiltration; (3) allergic to voriconazole.
The following information for patients enrolled are collected: demographics data [gender, age, weight, and body surface area (BSA) etc], laboratory test data [white blood cell count (WBC), neutrophil absolute value (NEU), hemoglobin (HGB), platelet count (PLT), total bilirubin (TBIL), aspartate transaminase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT),Albumin (ALB), alkaline phosphatase (ALP), creatinine (SCR), cystatin C (CYSC), endogenous creatinine clearance (Ccr)] and the concomitant drugs taken during VRC therapy [proton pump inhibitors (PPIs), including omeprazole, esomeprazole, pantoprazole, lansoprazole and rabeprazole, glucocorticoid (GLU), including dexamethasone and prednisone].